Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.
Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.
复制标题
DOI：
10.3390/v7092854
复制
发表时间：
2015-09-15
期刊：
影响因子：
--
通讯作者：
Tang J
中科院分区：
文献类型：
--
作者：
Kang L;Pan J;Wu J;Hu J;Sun Q;Tang J
全世界约有2.4亿人慢性感染乙型肝炎病毒（HBV），这对公共卫生构成重大挑战。目前治疗慢性HBV感染的目标是阻止HBV相关肝损伤和炎症进展为终末期肝病，包括肝硬化和肝细胞癌，因为我们无法消除慢性HBV感染。慢性HBV感染的现有治疗方法主要包括核苷/核苷酸类似物（NAs）、非NAs和免疫调节剂。然而，它们都不能清除慢性HBV感染。因此，迫切需要新一代抗hbv药物。在开发和测试抗慢性HBV感染的新疗法方面取得了进展。本文综述了国内外HBV新药研发的最新进展，并对近期的研究发展趋势和方向进行了展望。
Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver diseases, including cirrhosis and hepatocellular carcinoma, because we are unable to eliminate chronic HBV infection. Available therapies for chronic HBV infection mainly include nucleos/tide analogues (NAs), non-NAs, and immunomodulatory agents. However, none of them is able to clear chronic HBV infection. Thus, a new generation of anti-HBV drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection. This review aims to summarize the state of the art in new HBV drug research and development and to forecast research and development trends and directions in the near future.